High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 16, 1998

Primary Completion Date

December 31, 2002

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

filgrastim

DRUG

melphalan

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (17)

14642

University of Rochester Cancer Center, Rochester

33136

Sylvester Cancer Center, University of Miami, Miami

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37212

Veterans Affairs Medical Center - Nashville, Nashville

46202

Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis

53226

Medical College of Wisconsin, Milwaukee

53295

Veterans Affairs Medical Center - Milwaukee (Zablocki), Milwaukee

54449

CCOP - Marshfield Medical Research and Education Foundation, Marshfield

55416

CCOP - Metro-Minnesota, Saint Louis Park

55905

Mayo Clinic Cancer Center, Rochester

60201

CCOP - Evanston, Evanston

61602

CCOP - Illinois Oncology Research Association, Peoria

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

46202-5265

Indiana University Cancer Center, Indianapolis

02111

New England Medical Center Hospital, Boston

44106-5065

Ireland Cancer Center, Cleveland

37232-6838

Vanderbilt Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00003353 - High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis | Biotech Hunter | Biotech Hunter